|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM198217528 |
| 003 |
DE-627 |
| 005 |
20231223212240.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2010 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2010.04.009
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0661.xml
|
| 035 |
|
|
|a (DE-627)NLM198217528
|
| 035 |
|
|
|a (NLM)20483667
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Sanda, Srinath
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Short-term IL-1beta blockade reduces monocyte CD11b integrin expression in an IL-8 dependent fashion in patients with type 1 diabetes
|
| 264 |
|
1 |
|c 2010
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 05.08.2010
|
| 500 |
|
|
|a Date Revised 16.11.2017
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a OBJECTIVE: Interleukin 1-beta (IL-1beta) is a major inflammatory cytokine. Blockade of the IL-1beta pathway is therapeutically efficacious in type 2 diabetes, but the mechanistic effects on the immune system are incompletely understood
|
| 520 |
|
|
|a RESEARCH DESIGN: We administered an IL-1 receptor antagonist, anakinra, to 7 type 1 diabetes patients in order to investigate the immunologic and metabolic effects of this drug. Mechanistic assays were performed before and after drug administration
|
| 520 |
|
|
|a RESULTS: A novel signature was observed, with reduced serum interleukin 8 (IL-8) levels and reduced CD11b integrin expression on monocytes associated with increased CXCR1 expression
|
| 520 |
|
|
|a CONCLUSIONS: This set of linked phenotypes suggests that blockade of the IL-1beta pathway results in the reduced ability of mononuclear cells to traffic to sites of inflammation. Mechanistic studies from large scale trials using IL-1 blockade in type 1 diabetes should focus on changes in monocyte trafficking and the IL-8 pathway
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a CD11b Antigen
|2 NLM
|
| 650 |
|
7 |
|a Hypoglycemic Agents
|2 NLM
|
| 650 |
|
7 |
|a ITGAM protein, human
|2 NLM
|
| 650 |
|
7 |
|a Interleukin 1 Receptor Antagonist Protein
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-1beta
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-8
|2 NLM
|
| 700 |
1 |
|
|a Bollyky, Jenna
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Standifer, Nathan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nepom, Gerald
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hamerman, Jessica A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Greenbaum, Carla
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 136(2010), 2 vom: 01. Aug., Seite 170-3
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:136
|g year:2010
|g number:2
|g day:01
|g month:08
|g pages:170-3
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2010.04.009
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 136
|j 2010
|e 2
|b 01
|c 08
|h 170-3
|